A placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients
Read time: 1 mins
Last updated:11th Aug 2011
To evaluate the induction of clinical remission with Kappaproct given as an add-on treatment in two doses of 30 mg each compared to placebo.
|Study start date||2011-08-11|